Correlation Engine 2.0
Clear Search sequence regions


  • birth weight (3)
  • cohort (1)
  • distress (2)
  • female (1)
  • humans (1)
  • infant (2)
  • infant newborn (1)
  • neonates (1)
  • newborn (3)
  • preterm infants (2)
  • prognosis (1)
  • Sizes of these terms reflect their relevance to your search.

    Nationally, newborn screening programs use 17-hydroxyprogesterone (17-OHP) as the biomarker to detect the rare but potentially fatal inherited disease, congenital adrenal hyperplasia. However, this biomarker is highly variable, with a high false-positive rate of detection, particularly in neonates born preterm. Several studies have examined various clinical and genetic factors to explain the variability of 17-OHP in preterm infants. The purpose of this study was to replicate previous clinical and genetic associations with 17-OHP in a well-characterized cohort of 762 preterm infants. We replicated previous findings that respiratory distress syndrome (p = 2 x 10(-3)) is associated with higher 17-OHP. Higher 17-OHP and false positives were significantly associated with lower gestational age and birth weight, as previously reported. Incorporating gestational age and birth weight together decreases the false-positive rate.

    Citation

    Kelli K Ryckman, Daniel E Cook, Stanton L Berberich, Oleg A Shchelochkov, Susan K Berends, Tamara Busch, John M Dagle, Jeffrey C Murray. Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns. Journal of pediatric endocrinology & metabolism : JPEM. 2012;25(3-4):301-5

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 22768660

    View Full Text